Mamie Z. Li
YOU?
Author Swipe
View article: Identification of MYC synthetic lethal genes and networks
Identification of MYC synthetic lethal genes and networks Open
SUMMARY MYC is a potent oncogene that is frequently overexpressed in human tumors arising in different tissues. To date there are no approved therapies to directly antagonize oncogenic MYC and its role in driving tumorigenesis. As an alter…
View article: Author Correction: Defining E3 ligase–substrate relationships through multiplex CRISPR screening
Author Correction: Defining E3 ligase–substrate relationships through multiplex CRISPR screening Open
It has been brought to the authors' attention that the schematics in Fig. 5b were not described sufficiently clearly in the associated legend.The authors wish to clarify that the two identical flow cytometry plots shown in Fig. 5b depict a…
View article: Germline-encoded amino acid–binding motifs drive immunodominant public antibody responses
Germline-encoded amino acid–binding motifs drive immunodominant public antibody responses Open
Despite the vast diversity of the antibody repertoire, infected individuals often mount antibody responses to precisely the same epitopes within antigens. The immunological mechanisms underpinning this phenomenon remain unknown. By mapping…
View article: Table S4 from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells
Table S4 from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells Open
Gene signature for investigating human cancer datasets
View article: Table S5 from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells
Table S5 from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells Open
Genes in CARM1-KO signature
View article: Supplementary Data from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells
Supplementary Data from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells Open
Contains 16 supplementary figures and references
View article: Supplementary Data from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells
Supplementary Data from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells Open
Contains 16 supplementary figures and references
View article: Table S4 from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells
Table S4 from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells Open
Gene signature for investigating human cancer datasets
View article: Table S1 from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells
Table S1 from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells Open
CRISPR screen in tumor-infiltrating T cells
View article: Table S2 from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells
Table S2 from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells Open
RNA-seq of Carm1 KO CD8 T cells
View article: Table S6 from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells
Table S6 from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells Open
gRNA and primer sequences
View article: Table S6 from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells
Table S6 from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells Open
gRNA and primer sequences
View article: Data from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells
Data from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells Open
A number of cancer drugs activate innate immune pathways in tumor cells but unfortunately also compromise antitumor immune function. We discovered that inhibition of CARM1, an epigenetic enzyme and cotranscriptional activator, elicited ben…
View article: Table S1 from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells
Table S1 from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells Open
CRISPR screen in tumor-infiltrating T cells
View article: Table S2 from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells
Table S2 from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells Open
RNA-seq of Carm1 KO CD8 T cells
View article: Table S3 from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells
Table S3 from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells Open
RNA-seq of Carm1 KO tumor cells
View article: Data from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells
Data from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells Open
A number of cancer drugs activate innate immune pathways in tumor cells but unfortunately also compromise antitumor immune function. We discovered that inhibition of CARM1, an epigenetic enzyme and cotranscriptional activator, elicited ben…
View article: Table S5 from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells
Table S5 from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells Open
Genes in CARM1-KO signature
View article: Table S3 from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells
Table S3 from CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells Open
RNA-seq of Carm1 KO tumor cells
View article: Gain-of-function genetic screening identifies the antiviral function of TMEM120A via STING activation
Gain-of-function genetic screening identifies the antiviral function of TMEM120A via STING activation Open
Zika virus (ZIKV) infection can be associated with neurological pathologies, such as microcephaly in newborns and Guillain-Barre syndrome in adults. Effective therapeutics are currently not available. As such, a comprehensive understanding…
View article: CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells
CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells Open
A number of cancer drugs activate innate immune pathways in tumor cells but unfortunately also compromise antitumor immune function. We discovered that inhibition of CARM1, an epigenetic enzyme and cotranscriptional activator, elicited ben…
View article: Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality
Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality Open
SARS-CoV-2 (CoV2) antibody therapies, including COVID-19 convalescent plasma (CCP), monoclonal antibodies, and hyperimmune globulin, are among the leading treatments for individuals with early COVID-19 infection. The functionality of conva…
View article: Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality
Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality Open
COVID-19 convalescent plasma, particularly plasma with high-titer SARS-CoV-2 (CoV2) antibodies, has been successfully used for treatment of COVID-19. The functionality of convalescent plasma varies greatly, but the association of antibody …
View article: Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity
Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity Open
Profiling coronaviruses Among the coronaviruses that infect humans, four cause mild common colds, whereas three others, including the currently circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), result in severe infe…
View article: Integrated proteogenetic analysis reveals the landscape of a mitochondrial-autophagosome synapse during PARK2-dependent mitophagy
Integrated proteogenetic analysis reveals the landscape of a mitochondrial-autophagosome synapse during PARK2-dependent mitophagy Open
We explore the landscape of a mitochondrial-autophagosome synapse during mitophagy using proteomics and genetic screens.
View article: Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens
Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens Open
The toll of measles on the immune system Many of the deaths attributable to measles virus are caused by secondary infections because the virus infects and functionally impairs immune cells. Whether measles infection causes long-term damage…
View article: Diversified Application of Barcoded PLATO (PLATO-BC) Platform for Identification of Protein Interactions
Diversified Application of Barcoded PLATO (PLATO-BC) Platform for Identification of Protein Interactions Open
Proteins usually associate with other molecules physically to execute their functions. Identifying these interactions is important for the functional analysis of proteins. Previously, we reported the parallel analysis of translated ORFs (P…
View article: A Druggable Genome Screen Identifies Modifiers of α-Synuclein Levels via a Tiered Cross-Species Validation Approach
A Druggable Genome Screen Identifies Modifiers of α-Synuclein Levels via a Tiered Cross-Species Validation Approach Open
Accumulation of α-Synuclein (α-Syn) causes Parkinson's disease (PD) as well as other synucleopathies. α-Syn is the major component of Lewy bodies and Lewy neurites, the proteinaceous aggregates that are a hallmark of sporadic PD. In famili…